A short-acting GHRH-analogue research peptide used to investigate growth-hormone-releasing pathways and GH/IGF-1 signalling. The No-DAC form must be clearly distinguished from albumin-binding CJC-1295 with DAC because their molecular designs are not equivalent.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
CJC-1295 No DAC is a synthetic analog based on the biologically active 1–29 amino-acid region of growth hormone-releasing hormone (GHRH). It is commonly marketed under the name Modified GRF 1-29 and is distinguished from CJC-1295 with DAC by the absence of the Drug Affinity Complex (DAC) modification.
The absence of DAC produces a substantially shorter pharmacokinetic profile than the albumin-binding DAC form. This distinction is particularly relevant in laboratory research examining GHRH signaling, receptor activation, and patterns of growth hormone secretion.
CJC-1295 No DAC 10 mg is supplied as a research peptide for laboratory and scientific applications. The stated quantity refers to the amount of peptide contained in the product and should not be interpreted as a recommended human dosage.
A synthetic analogue of growth hormone-releasing hormone (GHRH) studied through the GHRH receptor and downstream GH/IGF-1 axis. Research areas include endocrine signalling, growth-hormone physiology and metabolic regulation.
A synthetic growth hormone secretagogue peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone signalling pathways. Its research landscape includes GH secretion, neuroendocrine regulation and metabolic signalling.
A synthetic growth hormone-releasing peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone secretory pathways. Its research landscape includes GH release, pituitary signalling and neuroendocrine regulation.
A two-component research formulation combining a GHRH-pathway analogue with a growth-hormone secretagogue, allowing investigation of two distinct signalling mechanisms converging on the GH axis. Both components and their quantities should remain explicitly identified.
A synthetic fragment derived from the C-terminal region of human growth hormone. Research focuses on the biological properties of this fragment and its relationship to metabolic and GH-associated signalling without representing the complete GH molecule.
A growth-hormone secretagogue investigated through ghrelin/GHS receptor signalling and downstream GH physiology. It provides a mechanistically different research route into the GH axis than GHRH analogues such as CJC-1295 and tesamorelin.